Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity
文献类型：期刊论文
| 作者 | Sun, Pu1,2; Meng, Ling-hua1,2
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2020-09-16 |
| 页码 | 8 |
| 关键词 | phosphoinositide 3-kinase (PI3K) PI3K inhibitors tumor microenvironment immune cells immunotherapy |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/s41401-020-00500-8 |
| 通讯作者 | Meng, Ling-hua(lhmeng@simm.ac.cn) |
| 英文摘要 | Immune system-mediated tumor killing has revolutionized anti-tumor therapies, providing long-term and durable responses in some patients. The phosphoinositide 3-kinase (PI3K) pathway controls multiple biological processes and is frequently dysregulated in malignancies. Enormous efforts have been made to develop inhibitors against class I PI3K. Notably, with the increasing understanding of PI3K, it has been widely accepted that PI3K inhibition not only restrains tumor progression, but also reshapes the immunosuppressive tumor microenvironment. In this review, we focus on the pivotal roles of class I PI3Ks in adaptive and innate immune cells, as well as other stromal components. We discuss the modulation by PI3K inhibitors of the tumor-supportive microenvironment, including eliminating the regulatory immune cells, restoring cytotoxic cells or regulating angiogenesis. The potential combinations of PI3K inhibitors with other therapies to enhance the anti-tumor immunity are also described. |
| WOS关键词 | PHOSPHATIDYLINOSITOL 3-KINASE-AKT PATHWAY ; ENDOTHELIAL GROWTH-FACTOR ; REGULATORY T-CELLS ; IMPAIRED B-CELL ; MATRIX METALLOPROTEINASES ; P110-GAMMA ISOFORM ; SUPPRESSOR-CELLS ; BETA-SELECTION ; P110-DELTA ; PI3K-GAMMA |
| 资助项目 | Personalized Medicines-Molecular Signature-based Drug Discovery and Development, Strategic Priority Research Program of the Chinese Academy of Sciences[XDA12020111] ; Personalized Medicines-Molecular Signature-based Drug Discovery and Development, Strategic Priority Research Program of the Chinese Academy of Sciences[XDA12020235] ; Personalized Medicines-Molecular Signature-based Drug Discovery and Development, Strategic Priority Research Program of the Chinese Academy of Sciences[XDA12050407] ; National Science and Technology Major Project Key New Drug Creation and Manufacturing Program[2018ZX09711002-011-014] ; National Science and Technology Major Project Key New Drug Creation and Manufacturing Program[2018ZX09711002-004-004] ; National Natural Science Foundation of China[81773760] ; National Natural Science Foundation of China[81973345] ; Fudan-SIMM Joint Research Fund[FU-SIMM20172005] |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000570042600003 |
| 出版者 | NATURE PUBLISHING GROUP |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/291138]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Meng, Ling-hua |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Materia Med, Div Antitumor Pharmacol, 501 Haike Rd, Shanghai 201203, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China |
| 推荐引用方式 GB/T 7714 | Sun, Pu,Meng, Ling-hua. Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity[J]. ACTA PHARMACOLOGICA SINICA,2020:8. |
| APA | Sun, Pu,&Meng, Ling-hua.(2020).Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity.ACTA PHARMACOLOGICA SINICA,8. |
| MLA | Sun, Pu,et al."Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity".ACTA PHARMACOLOGICA SINICA (2020):8. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。